Know Cancer

or
forgot password

Signaling in Tumorigenesis and Immunity


N/A
N/A
N/A
Open (Enrolling)
Both
Leukemia, Lymphoma

Thank you

Trial Information

Signaling in Tumorigenesis and Immunity


OBJECTIVES:

- To test whether the tumor suppressor candidate gene PDLIM2 is downregulated in human
cancers such as T-cell acute lymphoblastic leukemia (T-ALL) and to use the human
T-lymphotropic virus 1 (HTLV-1)-mediated in vitro transformation of human T cells as
control.

OUTLINE: Previously collected cancer and control tissues are analyzed for the expression
patterns of PDLIM2 and other control genes. Human T-cells isolated from human blood are also
co-cultured with HTLV-1-transformed T-cell lines.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Specimens (e.g., tissue, blood, and bodily fluids) of various cancer cells and or
tissues from de-identified patients such as T-cell acute lymphoblastic leukemia
(T-ALL)

- Normal control tissue

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

PDLIM2 expression patterns in cancer and control tissues

Safety Issue:

No

Principal Investigator

Gutian Xiao, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Pittsburgh

Authority:

United States: Federal Government

Study ID:

CDR0000723902

NCT ID:

NCT01520246

Start Date:

January 2012

Completion Date:

Related Keywords:

  • Leukemia
  • Lymphoma
  • adult acute lymphoblastic leukemia
  • childhood acute lymphoblastic leukemia
  • adult T-cell leukemia/lymphoma
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Lymphoma
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Name

Location